1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E52096BF1B04AC1500258B0A00291E93
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-establishing-mena-standards-field-medical-performance-excellence?opendocument
18
19opendocument
2034.239.151.124
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Establishing MENA Standards for Field Medical Performance Excellence

ID: 5803


Features:

9 Info Graphics

19 Data Graphics

300+ Metrics

9 Narratives


Pages/Slides: 33


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Establishing MENA Standards for Field Medical Performance Excellence”

STUDY OVERVIEW

Maximizing the performance of field medical teams in the dynamic and diverse Middle East and North Africa (MENA) region is critical for organizations seeking to maintain a competitive edge. Biopharma organizations must deploy actionable strategies to optimize operations, maximize stakeholder engagement, and evaluate performance effectively.

Best Practices, LLC conducted benchmarking research to deliver critical insights to field medical leaders, empowering them to navigate challenges and capitalize on opportunities within the Middle East and North Africa (MENA) market. By delving into key insights and benchmarks, the study equips field medical leaders with the necessary knowledge and strategies to drive field medical performance excellence across MENA.


KEY TOPICS

  • Effective Field Performance Metrics in the MENA Region
  • Framework for Field Medical Excellence
  • KOL Targeting and Engagement Levels in the MENA Region
  • Average MSL Time Allocation for KOL Interactions and Internal Activities
  • MENA Region Field Medical Staffing Footprint
  • Key Lessons Learned for Measuring MSL Impact in the MENA Region

KEY METRICS

  • Average total panel size supported by an individual MSL in the MENA region
  • Average number of monthly KOL/HCP and F2F meetings in the MENA region
  • MSL’s average time spent per thought leader interaction in the MENA region
  • Value assigned to each interaction type on the MSL scorecard – MENA region
  • Key metrics for evaluating and demonstrating the value of MSLs in the MENA region
  • Engagement metrics for non-tiered KOLs in the MENA region
  • Average annual field presence of MSLs in the MENA region
  • Time spent by MSLs on external, internal and logistics activities in the MENA region
  • Weekly MSL time allocation across activity streams in the MENA region
  • MSL engagement mix in the MENA region
  • Average number of field staff members in the MENA region
  • Span of control: MSLs per MSL manager in the MENA region

SAMPLE KEY FINDINGS

  • MENA Engagement Focus: The MENA region prioritizes engagement with Key Opinion Leaders (KOLs), which represent 62% of the overall focus. Healthcare Professionals (HCPs) account for 31%, while payers and other stakeholders constitute 1% and 6%, respectively.

METHODOLOGY

This study offers tailored benchmarks and insights focused on the MENA region. The data from this study is drawn from a larger global pool of field leaders, featuring 448 survey responses from over 100 biopharma manufacturers across the world. The data is meticulously segmented at the regional level to offer nuanced insights.


Additionally, Best Practices, LLC utilizes its proprietary Field Medical Excellence database to provide additional benchmarks tailored to align with varied portfolio considerations.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.